Postdoctoral Research Scientist: Drug Discovery in Friedreich's Ataxia
My research is focused on finding novel molecular targets for the treatment of Friedreich’s Ataxia, a devastating genetic disease that causes progressive gait and movement impairments leading to severe disability. Life expectancy is also greatly reduced mainly due to the development of a severe cardiomyopathy. The disease is caused by a GAA expansion in intron 1 of the FTX locus, encoding the mitochondrial protein Frataxin. Currently only few therapeutic options are available and only offer symptomatic relief. By investigating the molecular mechanisms that dictate the regulation of Frataxin levels in patients, we aim to find novel therapeutic targets.
I studied Medicinal Chemistry and Pharmaceutical Technologies at the University of Cagliari, Italy, where I graduated in 2011. I then started a PhD in Cancer Biology in the laboratory of Prof Sala, Brunel University, where I investigated the role of the Wnt receptor Fzd6 in breast cancer. In 2015 I started a Post-Doc in the same laboratory, where I used CRISPR/Cas9 gene editing tools to generate models of the rare tumour Adenoid Cystic Carcinoma. In January 2017 I joined the Wade-Martins laboratory.
Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage.
Corda G. and Sala A., (2017), Oncogenesis, 6
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.
Corda G. et al, (2017), J Pathol, 241, 350 - 361
Cutaneous cylindroma: it's all about MYB.
Corda G. and Sala A., (2016), J Pathol, 239, 391 - 393
Frizzled receptor 6 (FZD6) is required for the metastatic dissemination of breast cancer cells in vivo and serves as a biomarker of metastatic recurrence in patients
CORDA G., (2014)